01
Clinical
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
West China Hospital has launched a Phase I dose-escalation study for PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via intratumoral injection. The trial targets advanced solid tumors post-second-line therapy, utilizing a 3+3 design to assess safety and preliminary efficacy of lipid nanoparticle-formulated mRNA.